Acute Promyelocytic Leukemia | t(15;17)(q22;q12) | t(15;17)(PML,RARA) | PML-RARa bcr1 fusion protein, human
Item
diagnosis of apl based on morphological grounds, which will have to be confirmed by the presence of t(15;17) and/or pml-rara rearrangement with characterization of the bcr subtype (pml-rar characterization).
boolean
C0023487 (UMLS CUI [1])
C1515724 (UMLS CUI [2])
C1979990 (UMLS CUI [3])
C3493223 (UMLS CUI [4])
Patients Untreated
Item
untreated patients.
boolean
C0030705 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
ID.3
Item
no contraindication to intensive chemotherapy (especially well documented cardiac contraindication to idarubicin).
boolean
ID.4
Item
in female patients: absence of pregnancy and adequate contraceptive methods (due to teratogenetic effects of atra in early pregnancy).
boolean
Arsenic AND/OR arsenic compound Hypersensitivity Absent
Item
absence of hypersensitivity to arsenic derivatives.
boolean
C0300979 (UMLS CUI [1,1])
C0020517 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
ID.6
Item
no qt interval prolongation or complete atria-ventricular block.
boolean
Informed Consent
Item
written informed consent.
boolean
C0021430 (UMLS CUI [1])
Patients Treated
Item
patients already treated.
boolean
C0030705 (UMLS CUI [1,1])
C1522326 (UMLS CUI [1,2])
ID.9
Item
patients with contraindication to intensive chemotherapy, especially well documented cardiac contraindication to idarubicin.
boolean
ID.10
Item
in female patients: pregnancy or absence of adequate contraceptive methods
boolean
ID.11
Item
qt interval prolongation or complete atria-ventricular block.
boolean
Hypersensitivity Arsenic AND/OR arsenic compound
Item
hypersensitivity to arsenic derivatives.
boolean
C0020517 (UMLS CUI [1,1])
C0300979 (UMLS CUI [1,2])